TNFSF11 and plasma cell myeloma: Agents that disrupt osteoclastogenesis, such as bisphosphonates and anti-RANKL blocking antibody (denosumab), have shown clinical efficacy in various cancer cases, including multiple myeloma, and could be promising add-ons to the combination cancer-metabolism-targeting agents.